📈 Trending 🗄 Archive 💬 Ask ＋ Join⌂ House

Loop Biotech

biology, engineered

Live · refreshes automatically

⚡ The Brief - today's Biotech, synthesized
Top story Medicare finalizes rule cutting billions from 340B drug payments and expanding site-neutral payments in 2027
Biopharmadive

The rule reduces reimbursement for drugs purchased under the 340B discount program and equalizes payments across care sites, drawing strong opposition from hospitals.

full coverage →medicarepolicydrug-pricing
HealthcarediveMedicare will cut billions from 340B, expand site-neutral payments in 2027ModernhealthcareMedicare hospital outpatient pay to rise 2.3% in 2027FiercehealthcareHospital groups rail against CMS' proposed 340B changes, site-neutral paymentsMedtechdiveMedicare slashes 340B payments, broadens site-neutral policies in proposed 2027 payment ruleHealthleadersmedia340B Cuts Softened, Site-Neutral Expansion Progresses in CMS CY 2027 OPPS Final RuleParagoninstituteNew Medicare Payment Rules (OPPS and PFS) Show Trump Administration’s Focus on Site Neutral Payments and Reducing Medicare’s Market DistortionsYahooMedicare will cut billions from 340B, expand site-neutral payments in 2027
FDA accepts uniQure's BLA for Huntington's disease gene therapy, granting priority review
Pharmaceutical-technology

The filing sets up a regulatory decision on what would be a first gene therapy for the inherited neurodegenerative disease, though approval remains uncertain.

full coverage →gene-therapyfdahuntingtons
NrtimesFDA grants priority review to Huntington’s disease gene therapyMedicaldailyFDA accepts uniQure's one-time Huntington's gene therapy for review-but approval is still uncertainBiopharminternationalFDA Accepts uniQure’s Huntington’s Disease Gene Therapy BLA for Priority ReviewNeurologyliveFDA Grants Priority Review to Huntington Disease Gene Therapy BLAHdbuzzFDA sets May 2027 decision date on AMT-130 gene therapy for HDGenengnewsFDA Sets May 1 PDUFA Action Date for uniQure’s Huntington’s Disease Gene TherapyNeurologyadvisorFDA Grants Priority Review to Novel Huntington Disease Gene TherapyTradingviewuniQure gains FDA Priority Review for Huntington's disease gene therapyAllsciFDA grants uniQure’s Huntington’s gene therapy Priority Review on small, externally controlled datasetTokenpostuniQure Says FDA Grants Priority Review to Huntington’s Gene TherapyGurufocusFDA Accepts uniQure's BLA for Huntington's Gene Therapy, Ticker QURE Sees Mixed SignalsGlobenewswireuniQure Announces FDA Acceptance and Priority Review of thePluangFDA accepts and grants priority review to uniQu...BiospaceUniQure files for FDA, UK approval of first gene therapy for Huntington’s disease
Revolution Medicines' pancreatic cancer drug Rasonque posts one of the best oncology launches in history
Biopharmadive

Early sales blew past Wall Street expectations, prompting analysts to reset projections for the drug despite company caution about drawing conclusions too soon.

full coverage →oncologyearningsrevolution-medicines
STATSTAT+: Revolution Medicines’ pancreatic cancer drug has stunning commercial debutInvestorsBiotech Earnings: Who Won, Who Lost And Who Pulled Off A 'Historic' Launch?PluangNew pancreatic cancer drug Rasonque posts $198M sales in Q3, far exceeding forecasts.PancanFirst RAS Inhibitor Extends Survival in Previously Treated Metastatic Pancreatic Adenocarcinoma: What You Need to KnowThe New York TimesA $480,000-a-Year Pill Reflects a New Normal for Cancer DrugsFortuneWhy Wall Street sees a $39,800 pancreatic cancer pill as proof of a much bigger betMarketscaleRasonque’s 13.2-month survival result is about to hit hospital formulariesPeoplespharmacyPancreatic Cancer Treatment: Rasonque = Breakthrough, Vitamin C = CricketsGenomewebAmid Rasonque Excitement, Biomarker Testing Remains Important in Pancreatic Cancer CareMarketWatchThis pancreatic cancer treatment is on track for ‘one of the best drug launches of all time’
Madrigal's former clinical development head files whistleblower suit alleging Rezdiffra safety cover-up
Fiercepharma

The lawsuit raises questions about safety disclosures for the first approved treatment for MASH liver disease.

full coverage →legalsafetymadrigal
FiercebiotechApplied Therapeutics CEO steps down in wake of FDA rejection, warning letter and investor lawsuitFiercepharmaMadrigal’s former clinical development head files whistleblower lawsuit alleging Rezdiffra safety cover-up
CVS to split into two companies, separating Aetna and Caremark from its retail pharmacies
Biopharmadive

The breakup reverses years of vertical integration in healthcare and challenges the assumption that larger conglomerates deliver better results.

full coverage →cvshealthcarecorporate
ModernhealthcareWhy CVS is breaking up its pharmacy empire nowHealthcarediveCVS to split into two companies in stunning strategic about-faceMedicaldailyCVS plans to split its pharmacies from Aetna and Caremark by 2028-here's what customers need to knowCNBCCVS Health plans to split itself up. Here's why a breakup could make sense nowReutersCVS to break up $117 billion business, separating pharmacies from insurance; shares fallLibnCVS Health, with Long Island stores, to split into two companiesUpriseriCVS Plans to Separate 9,000 Pharmacies From Aetna and CaremarkInsurancebusinessmagCVS to split in two, keeping Aetna with Caremark as insurance margins recoverThe Wall Street JournalCVS Will Break Off Its Namesake PharmaciesClick2houstonCVS Health plans to split into two companies, separating pharmacies from health insurance businessCnnCVS to split into two companies, in major breakup of its $117 billion healthcare empireMassliveCVS split: Why the pharmacy chain is breaking up and what it means for customersFiercehealthcareCVS Health plans to split pharmacy business from Aetna, CaremarkHealthcare-brewWhat CVS’s split means for retail pharmacy
Novo Nordisk's Wegovy pill sales top Wall Street forecasts in third quarter
Biopharmadive

The oral obesity drug's strong numbers widen Novo's early lead over Eli Lilly in the pill segment of the weight loss market.

full coverage →obesityearningsnovo-nordisk
YahooNovo Nordisk CEO: Wegovy pill 'exceeded our expectations'BiggoNovo Nordisk Lifts 2026 Guidance as Wegovy Pill Sales Top ForecastsReutersNovo hikes outlook again as it speeds up Wegovy pill rolloutFirstwordpharmaNovo's upbeat forecast can't overcome disappointments from oral Wegovy, CagriSemaTipranksNovo Reports Q3 Beat, Raises 2026 Sales Forecast on Obesity Demand; NVO Stock Jumps 5%YahooNovo gets much-needed lift as Wegovy pill tops Wall Street forecasts
FDA grants priority review to Huntington's disease gene therapy
Nrtimes

A second Huntington's gene therapy candidate advances in the regulatory pipeline amid rising interest in one-time treatments for the disease.

full coverage →gene-therapyfdahuntingtons
FiercebiotechFDA grants uniQure’s Huntington’s gene therapy priority review, teeing up ‘defining milestone’HuntingtonsdiseasenewsFDA grants priority review to gene therapy for Huntington’sNeurologyliveFDA Grants Priority Review to Huntington Disease Gene Therapy BLANeurologyadvisorFDA Grants Priority Review to Novel Huntington Disease Gene TherapyTokenpostuniQure Says FDA Grants Priority Review to Huntington’s Gene TherapyAllsciFDA grants uniQure’s Huntington’s gene therapy Priority Review on small, externally controlled datasetInklHuntington's Gene Therapy AMT-130 Gets FDA Priority Review and a May 2027 Decision Date, Advisory Panel PlannedPluangFDA accepts and grants priority review to uniQu...EmprFDA Grants Priority Review to Novel Huntington Disease Gene Therapy
VeonGen aligns with FDA on Phase 3 design for VG801 Stargardt disease gene therapy
Biopharminternational

The agreement on a pivotal trial plan moves the company's treatment for the inherited retinal disorder toward late-stage development.

full coverage →gene-therapyfdaophthalmology
ManilatimesVeonGen Announces FDA Alignment on Pivotal Phase 3 Development and Clinical Progress of VG801 for Stargardt DiseaseGenomewebVeonGen, FDA Align on Phase III Trial Plan for Stargardt Disease Gene Therapy
China restricts investigator-initiated biotech clinical trials after patient deaths
STAT

The crackdown leaves rare disease families and US investors facing uncertainty as a once-booming pipeline of trials slows.

full coverage →chinaclinical-trialsregulation
StraitstimesPatient death in China gene-editing trial draws fire: JournalFiercebiotechAfter 2 undisclosed gene therapy deaths, can China’s alternative regulatory path still be trusted?EndpointsThree deaths in China shake trust in the country's speedy clinical trial systemBloombergChild Died in Chinese Biotech Firm’s Gene Editing TrialTechtimesHuidaGene Hid Boy’s Gene Therapy Death for 12 Months: China Trial System FailedNatureChina’s fast-track clinical trials are in the spotlight after child deaths
T-Therapeutics raises $133M Series B for bispecific antibody programs
Biopharmadive

The startup targets previously undruggable cancer targets and seeks more selective treatments for autoimmune disease.

full coverage →fundingbispecificsbiotech
FiercebiotechT-Therapeutics raises $133M series B for bispecific pipeline with Big Pharma backers in towInvestorsinhealthcareUK: T-Therapeutics closes oversubscribed US$133m Series B to advance TCR bispecific programmes to clinical proof-of-conceptEuropean-biotechnologyT-Therapeutics raises $133M to bring TCR bispecifics into clinicBioxconomyT-Therapeutics nets $133m to push T cell engagers toward the clinicYahooT-Therapeutics reloads with a $133M megaround for bispecifics
Wisconsin reports first measles death since 1990 as infant dies
STAT

The death underscores resurgent measles transmission amid declining vaccination rates in parts of the US.

full coverage →public-healthvaccinesmeasles
ThehillWisconsin reports first measles death since 1990NbcnewsWisconsin reports its first measles death in decades, the third in the U.S. this weekJsonlineInfant's death from measles is first in Wisconsin since 1990CidrapA baby in Wisconsin has died from measles, the 3rd such US death this weekAbc7chicagoBaby dies from measles amid ongoing outbreak in Wisconsin; 1st death of its kind since 1990, health officials sayKgwBaby dies from measles in WisconsinWausaupilotandreviewInfant dies of measles in Wisconsin, the state’s first measles death since 1990WbayInfant dies in Wisconsin measles outbreak, first such death since 1990NbcchicagoInfant becomes first child to die from measles in Wisconsin since 1990CbsnewsInfant dies in measles outbreak in southwest WisconsinUpiWis. reports first measles death in 35 yearsBringmethenewsInfant dies of measles in Wisconsin, the first such fatality since 1990Wmtv15newsInfant dies in Wisconsin amid measles outbreak
Trial of failed sickle cell gene-editing therapy shows signs of a possible comeback
STAT

The program was halted three years ago after the first patient suffered a serious adverse event, and new developments may revive it.

full coverage →gene-editingsickle-cellclinical-trials
ReutersAgios scraps sickle cell treatment after trial shows limited benefitChemistryworldCould Crispr cure HIV?NatureA turning point for gene editing in severe blood disordersYalemedicineCasgevy and Lyfgenia: Two Gene Therapies Approved for Sickle Cell DiseaseBiopharmadiveFDA places formal hold on two Intellia CRISPR trialsClevelandclinicTrial of Gene Therapy to Treat Sickle Cell Disease Reports Initial Positive ResultsPbsExperimental gene editing helped a desperately ill baby thrive. Scientists say it could someday treat millionsBbcHunter syndrome: Boy with rare condition amazes doctors after world-first gene therapyMedicalxpressHow a CRISPR sickle cell therapy moved from lab to clinical trial
The daily briefTop stories, once a day. Or build your own feed.